Lifecare has incorporated a new subsidiary, Lifecare Chemistry Ltd, located inBath, UK. - This move gives us clear strategic advantages related to chemical researchdevelopment and builds on the close and good collaboration Lifecare already hasestablished with the University of Bath, says CEO Joacim Holter.
Since 2020, Lifecare has worked together with researchers at the University ofBath to provide expertise for advancing the implantable glucose sensor.Professor Tony James and Dr. Jordan Gardiner at the Department of Chemistry aredeveloping glucose specific chemical receptors which will replace the existingbiobased receptors providing more reliability within the sensing sphere.
The CEO of Lifecare states this team will clearly improve the quality assuranceof Lifecare's flagship product for people with diabetes. - Tony James has an outstanding academic record. He is a Fellow of the RoyalSociety of Chemistry and he has developed a broad interdisciplinary approach toresearch. He has published over 418 publications, including two books, 9 bookchapters and 407 papers in international peer reviewed journals. Professor Jamesis also the named inventor on 25 international patents, delivered 252 invitedlectures within the UK and internationally and he has more than 27.000citations. Together with up-and-coming Dr. Jordan Gardiner they are a remarkableasset for Lifecare, Holter points out.
- Due to business strategic considerations, now is the time to build on thisrewarding research collaboration, formalizing it through a new subsidiary basedin Bath. This will obviously give an advantage in terms of increased ownershipof the research results. The establishment of a UK subsidiary will also put usin a position eligible for public support schemes and grants to the benefit ofour overall development, Holter says.
The director of Lifecare greatly appreciated the collaboration with theuniversity, which was recently named university of the year in the UK by theTimes and the Sunday Times.- Advancing our nano-pressure sensor system from biological to chemicalreceptors for glucose monitoring is very much welcomed at Lifecare AS. Our goalof contributing to help people with diabetes, comprising more than 537 millionpeople globally, is becoming more of a reality because of the world-classscientific expertise from the University of Bath, states Joacim Holter atLifecare.
For further information, please contact: Joacim Holter, CEO, Lifecare AS, joacim.holter@lifecare.attme.dev, +47 40 05 90 40
This stock exchange announcement was published by Joacim Holter, CEO at LifecareAS, on 08.11.22 at 08:43 CET.